Literature DB >> 3390901

Characteristics of chylomicron remnant uptake into rat liver.

M Huettinger1, H Retzek, M Eder, H Goldenberg.   

Abstract

We have investigated uptake of 125I-labeled chylomicron remnants into livers of rats in the presence of lactoferrin. This glycoprotein possesses a cluster of four arginines at the N-terminus similar to the arginine rich binding sequence of apoprotein E (apoE) to the LDL-receptor. We found that this protein inhibits uptake of 125I-chylomicron remnant radioactivity by 50% when measured as accumulation of radioactivity into the intact organ, and even more pronounced, over 75%, when measured as uptake into an endosomal fraction prepared therefrom. Provided that the arginine rich sequence is responsible for the inhibition, a similarity in the characteristics of binding of apoE to the LDL (low density lipoprotein)- and chylomicron remnant-receptor is likely. Second, transferrin having sequence homologies with lactoferrin, but lacking the arginine cluster does not interfere with chylomicron remnant uptake. Third, lactoferrin does not inhibit the uptake of chylomicron remnants by the spleen, which is most likely mediated through scavenger cells by a mechanism different from the chylomicron remnant uptake system of the liver. We hypothesize from this that lactoferrin specifically interferes with the physiologically relevant chylomicron remnant uptake system of the liver. Investigation of the mechanism of this inhibition will provide information about the physical characteristics of the remnant receptor system.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3390901     DOI: 10.1016/s0009-9120(88)80093-6

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  10 in total

1.  Recognition of chylomicron remnants and beta-migrating very-low-density lipoproteins by the remnant receptor of parenchymal liver cells is distinct from the liver alpha 2-macroglobulin-recognition site.

Authors:  M C van Dijk; G J Ziere; W Boers; C Linthorst; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1991-11-01       Impact factor: 3.857

2.  In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel nonviral vector.

Authors:  T Hara; Y Tan; L Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-23       Impact factor: 11.205

3.  Healthy birth weight results in higher vitamin A storage in neonate piglets administered high-dose supplements.

Authors:  Emily K Heying; Elizabeth Hovel; Sherry A Tanumihardjo
Journal:  Exp Biol Med (Maywood)       Date:  2015-02-13

4.  The role of lipoprotein lipase and apoprotein E in the recognition of chylomicrons and chylomicron remnants by cultured isolated mouse hepatocytes.

Authors:  S Chang; N Maeda; J Borensztajn
Journal:  Biochem J       Date:  1996-08-15       Impact factor: 3.857

5.  Human recombinant apolipoprotein E redirects lipopolysaccharide from Kupffer cells to liver parenchymal cells in rats In vivo.

Authors:  P C Rensen; M Oosten; E Bilt; M Eck; J Kuiper; T J Berkel
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

Review 6.  The role of lactoferrin in atherosclerosis.

Authors:  Cailong Chen; Menglan Lu; Zheng Zhang; Liqiang Qin
Journal:  Biometals       Date:  2022-09-02       Impact factor: 3.378

7.  Surface composition regulates clearance from plasma and triolein lipolysis of lipid emulsions.

Authors:  I Arimoto; C Matsumoto; M Tanaka; K Okuhira; H Saito; T Handa
Journal:  Lipids       Date:  1998-08       Impact factor: 1.880

8.  Recognition of lactoferrin and aminopeptidase M-modified lactoferrin by the liver: involvement of proteoglycans and the remnant receptor.

Authors:  G J Ziere; J K Kruijt; M K Bijsterbosch; T J van Berkel
Journal:  Biochem J       Date:  1996-01-01       Impact factor: 3.857

9.  Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes.

Authors:  P Sinnis; T E Willnow; M R Briones; J Herz; V Nussenzweig
Journal:  J Exp Med       Date:  1996-09-01       Impact factor: 14.307

Review 10.  Peptides from Natural or Rationally Designed Sources Can Be Used in Overweight, Obesity, and Type 2 Diabetes Therapies.

Authors:  Mayara C F Gewehr; Renata Silverio; José Cesar Rosa-Neto; Fabio S Lira; Patrícia Reckziegel; Emer S Ferro
Journal:  Molecules       Date:  2020-02-29       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.